On March 1, 2023 Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Alessa Therapeutics reported their collaboration for developing a new oncology drug product leveraging Alessa’s expertise on sustained localized drug delivery and the Celanese VitalDose EVA drug delivery platform (Press release, Celanese, MAR 1, 2023, View Source [SID1234628022]). The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients that will limit systemic side effects and improve overall treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The commercial flexibility, responsiveness and technical support provided by Celanese has enabled the rapid progression of our drug candidate," says Maithili Rairkar, Vice President of Technical Operations at Alessa Therapeutics. "We look forward to progressing this innovative local drug delivery approach beginning with human studies later this year."

"Our new collaboration with Alessa Therapeutics underscores our commitment to optimize therapeutics through drug delivery innovation for oncology patients," said Karen Chen, Global Business Strategy Leader for Oncology at Celanese. "Delivery can be a fundamental, and oftentimes overlooked, part of a drug’s success, and we believe that our contribution to Alessa’s work can make a meaningful difference in the lives of cancer patients."